Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Pieter-Jan De Sutter"'
Autor:
Amber De Bleeckere, Sara Van den Bossche, Pieter-Jan De Sutter, Tine Beirens, Aurélie Crabbé, Tom Coenye
Publikováno v:
Biofilm, Vol 5, Iss , Pp 100106- (2023)
The presence of Pseudomonas aeruginosa biofilms in cystic fibrosis (CF) patients suffering from chronic lung infections contributes to the failure of antimicrobial therapy. Conventionally, the minimal inhibitory concentration (MIC) is determined to a
Externí odkaz:
https://doaj.org/article/43fc9370dd004214bf12dbf72dfefe0f
Autor:
Pieter‐Jan De Sutter, Maxime Van Haeverbeke, Eva Van Braeckel, Stephanie Van Biervliet, Jan Van Bocxlaer, An Vermeulen, Elke Gasthuys
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 11, Iss 8, Pp 951-966 (2022)
Abstract Cystic fibrosis (CF) has been linked to altered drug disposition in various studies. However, the magnitude of these changes, influencing factors, and underlying mechanisms remain a matter of debate. The primary aim of this work was therefor
Externí odkaz:
https://doaj.org/article/8274e782a92e4d6d81b86237fa6c5c12
Publikováno v:
Pharmaceutics, Vol 15, Iss 9, p 2348 (2023)
The volume of distribution at steady state (Vss) in neonates is still often estimated through isometric scaling from adult values, disregarding developmental changes beyond body weight. This study aimed to compare the accuracy of two physiologically
Externí odkaz:
https://doaj.org/article/3287cb894b1b47cf9172ee031c0510b4
Autor:
Pieter-Jan De Sutter, Pieter De Cock, Trevor N Johnson, Helen Musther, Elke Gasthuys, An Vermeulen
Publikováno v:
Drug Metabolism and Disposition. 51:499-508
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d19b62475cf5b9e5027263ef4fe820f8
https://doi.org/10.1124/dmd.122.001129
https://doi.org/10.1124/dmd.122.001129
Autor:
An Vermeulen, Petra Schelstraete, Jan Van Bocxlaer, Pieter-Jan De Sutter, Elke Gasthuys, Stephanie Van Biervliet, Eva Van Braeckel
Publikováno v:
Clinical Pharmacokinetics. 59:1551-1573
Cystic fibrosis is a lethal inherited disease that affects multiple organs. To provide optimal pharmacological treatment of comorbidities associated with cystic fibrosis, relevant alterations in pharmacokinetics must be known. The objective of this s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::089c38c38517cdfb8ed12bd129567f7b
https://doi.org/10.1007/s40262-020-00932-9
https://doi.org/10.1007/s40262-020-00932-9
Publikováno v:
Clinical Pharmacokinetics. 61:335-336
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4b388b6d11790580c945608692f4f6db
https://doi.org/10.1007/s40262-021-01100-3
https://doi.org/10.1007/s40262-021-01100-3